ARCHIVES

FDA Committee Okays Carboplatin For Second Line Ovarian Cancer

This article is from The Cancer Letter archive.

Vol. 15 No. 01 | January 6, 1989

Download PDF Visit The Full Archive

Related Articles

NCCN Updates Breast Cancer Guidelines for Patients

October 31, 2003

Troubled Roswell Park Cancer Institute Bets On Recruitment To Regain Its Luster.

January 19, 2001

NCCN’s First Physician CEO: Robert Carlson Pledges Broader Research and Policy Agenda

October 5, 2012

NCI To Fund More SPORE Grants In FY95 Recopetition

March 11, 1994

SWOG Opens Phase II Trial Of CuraGen’s HDAC Inhibitor For B-Cell Lymphoma

September 29, 2006

Fisher Address Gap Between Clinicians Investigators, A Threat To Patient Welfare

May 28, 1993